Valneva SE (VALN)

NASDAQ: VALN · IEX Real-Time Price · USD
7.92
+0.30 (3.94%)
At close: Apr 22, 2024, 3:43 PM
8.07
+0.15 (1.89%)
After-hours: Apr 22, 2024, 4:00 PM EDT
3.94%
Market Cap 551.04M
Revenue (ttm) 170.79M
Net Income (ttm) -112.70M
Shares Out 69.58M
EPS (ttm) -1.56
PE Ratio n/a
Forward PE 10,000.00
Dividend n/a
Ex-Dividend Date n/a
Volume 2,891
Open 7.76
Previous Close 7.62
Day's Range 7.76 - 7.92
52-Week Range 6.58 - 17.05
Beta 0.83
Analysts Strong Buy
Price Target 21.50 (+171.47%)
Earnings Date May 2, 2024

About VALN

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by c... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 6, 2021
Employees 676
Stock Exchange NASDAQ
Ticker Symbol VALN
Full Company Profile

Financial Performance

In 2023, Valneva SE's revenue was 153.71 million, a decrease of -57.46% compared to the previous year's 361.30 million. Losses were -101.43 million, -29.21% less than in 2022.

Financial numbers in EUR Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for VALN stock is "Strong Buy." The 12-month stock price forecast is $21.5, which is an increase of 171.47% from the latest price.

Price Target
$21.5
(171.47% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate

Saint-Herblain (France), March 26, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the initiation of a Phase 1 clinical trial to investigate the

27 days ago - GlobeNewsWire

Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F

Saint-Herblain (France), March 25, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the filing, on March 22, 2024, of its 2023 Universal Registration...

4 weeks ago - GlobeNewsWire

Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C.

Saint-Herblain (France), March 21, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced it will present on its single-shot chikungunya vaccine, IXCHIQ®, ...

4 weeks ago - GlobeNewsWire

French biotech company Valneva raises product sales guidance

French biotech company Valneva on Wednesday raised its product sales guidance and said it now expects revenues of between 170 million euros and 190 million euros ($184.72 million to $206.45 million) i...

4 weeks ago - Reuters

Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook

Total revenues of €153.7 million, including product sales of €144.6 million Product sales surpassed pre-pandemic (2019) sales by 12% and 2022 sales by 26% Excluding COVID-19 vaccine sales, product sal...

4 weeks ago - GlobeNewsWire

Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed

Saint-Herblain (France), March 18, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced an agreement with funds managed by leading U.S. healthcare invest...

5 weeks ago - GlobeNewsWire

Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences

Saint-Herblain (France), March 4, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will participate at upcoming investor c...

7 weeks ago - GlobeNewsWire

U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva's Single-Dose Chikungunya Vaccine IXCHIQ®

U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva's Single-Dose Chikungunya Vaccine IXCHIQ ®

7 weeks ago - GlobeNewsWire

Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance

Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance Total revenues of €153.7 million, including product sales of €144.6 million Product sales surpassed pre-pandemic (2019) sa...

2 months ago - GlobeNewsWire

Valneva sells chikungunya vaccine priority review voucher for $103 mln

French vaccine maker Valneva said on Monday it sold the priority review voucher (PRV) it received from the U.S. Food and Drug Administration (FDA) for $103 million.

2 months ago - Reuters

Valneva Announces Sale of Priority Review Voucher for $103 Million

Saint-Herblain (France), February 5, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced it sold the Priority Review Voucher (PRV) it received from the ...

2 months ago - GlobeNewsWire

Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine

Saint-Herblain (France), January 10, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the first participant has been vaccinated in the Phase 2 clinical trial evaluating the s...

3 months ago - GlobeNewsWire

Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and Oddo BHF Forum

Saint-Herblain (France), January 4, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces that members of its management team including Thomas Lingelbach,...

3 months ago - GlobeNewsWire

Valneva Provides Updated 2023 Financial Guidance

Saint-Herblain (France), December 29, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Company is modifying its financial guidance for 2023....

4 months ago - GlobeNewsWire

Valneva Shareholders Approve EGM Resolutions Including the Transition to a Board of Directors

Anne-Marie Graffin is appointed as Chair of the Board of Directors Saint-Herblain (France), December 20, 2023 –Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announ...

4 months ago - GlobeNewsWire

Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15

Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15 9,437* participants enrolled at sites across the U.S., Europe and Canada in areas where Lyme d...

Other symbols: PFE
5 months ago - GlobeNewsWire

Valneva Reports Positive 24-Month Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®

Valneva Reports Positive 24-Month Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ ®

5 months ago - GlobeNewsWire

Valneva says EU regulator accepts its chikungunya vaccine application

French drugmaker Valneva said on Monday that the application for its vaccine candidate against mosquito-borne viral disease chikungunya was accepted by the European Medicines Agency (EMA) which would ...

5 months ago - Reuters

EMA Accepts Valneva's Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment

Saint-Herblain (France), November 27, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) has performed a techn...

5 months ago - GlobeNewsWire

Valneva Announces the Availability of Documentation for its Extraordinary General Meeting including Planned Changes to its Future Board of Directors

Saint-Herblain (France), November 15, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the availability of documentation for its Extraordinary Genera...

5 months ago - GlobeNewsWire

Valneva Reports Positive Pivotal Phase 3 Immunogenicity Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate

Saint-Herblain (France), November 13, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positive pivotal Phase 3 immunogenicity data in adolescents for...

5 months ago - GlobeNewsWire

FDA approves Valneva's Chikungunya vaccine for adults

French drugmaker Valneva said on Friday the U.S. Food and Drug Administration (FDA) has approved its Chikungunya single-dose vaccine in individuals aged 18 and above.

5 months ago - Reuters

Valneva Announces U.S. FDA Approval of World's First Chikungunya Vaccine, IXCHIQ®

Saint-Herblain (France), November 10, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the U.S. Food and Drug Administration (FDA) has approved ...

5 months ago - GlobeNewsWire

US FDA approves Valneva's chikungunya vaccine

The U.S. Food and Drug Administration (FDA) on Thursday approved Valneva's single-shot vaccine for individuals 18 years of age and older who are at increased risk of exposure to chikungunya virus.

5 months ago - Reuters

Valneva Reports Nine-Month 2023 Financial Results and Provides Corporate Updates

Product sales of €106.1 million, an increase of 42.6% compared to the first nine months of 2022 IXIARO® and DUKORAL® sales benefited from a continued recovery of the travel industry Total revenues of ...

5 months ago - GlobeNewsWire